A randomized, open-label trial comparing methadone and Levo-Alpha- Acetylmethadol (LAAM) in maintenance treatment of opioid addiction

Pharmacopsychiatry

Volumn 42, Issue 1, 2009, Pages 1-8

  Wolstein, J ^a,b   Gastpar, M ^a   Finkbeiner, T ^a   Heinrich, C ^c   Heitkamp, R ^d   Poehlke, T ^e   Scherbaum, N ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF BAMBERG   (Germany)

^c Institute for Medical Research Management and Biometrics GmbH   (Germany)

^d Methadone Maintenance Clinic   (Germany)

^e Methadone Maintenance Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LEVACETYLMETHADOL; METHADONE; ACETYLMETHADOL; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABUSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HUMAN; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; NAUSEA; OPIATE ADDICTION; PRIORITY JOURNAL; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; TREATMENT DURATION; URINALYSIS; VOMITING; WITHDRAWAL SYNDROME; COMPARATIVE STUDY; EUROPE; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SPIROMETRY; SURVIVAL; URINE;

ADULT; ANALGESICS, OPIOID; EUROPE; FEMALE; HUMANS; MALE; METHADONE; METHADYL ACETATE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPIROMETRY; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 64749104381     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1083818     Document Type: Article

References (52)

1. American Psychiatric Association. Position statement on methadone maintenance treatment. Am J Psychiatry 1994 ; 151 : 792-794
2. Anglin MD , Conner BT , Annon J et al. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status. Addiction 2007 ; 102 : 1432-1442
3. Bauer P , Kieser M. A unifying approach for confidence intervals and testing of equivalence and difference. Biometrika 1996 ; 83 : 934-937
4. Binchy JM , Molyneux EM , Manning J. Accidental ingestion of methadone by children in Merseyside. BMJ 1994 ; 308 : 1335-1336
5. Blaschke D , Parwani AS , Huemer M et al. Torsade de pointes during combined treatment with risperidone and citalopram. Pharmacopsychiatry 2007 ; 40 : 294-295
6. Clark N , Lintzeris N , Gijsbers A et al. LAAM maintenance vs. methadone maintenance for heroin dependence. (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software 2003
7. Clinical Global Impressions. In: Internationale Skalen f ür Psychiatrie (Collegium Internationale Psychiatriae Scalarum). Beltz Verlag, G ö ttingen 1996
8. Derogatis CR. SCL-90. Administration, Scoring & Procedures. Manual- I for the (revised) version and other instruments of the Psychopathology Rating Scale Series. Johns Hopkins University School of Medicine 1977
9. Dyer KR , White JM. Patterns of symptom complaints in methadone maintenance patients. Addiction 1997 ; 92 : 1445-1455
10. Dyer KR , Foster DJ , White JM et al. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration- effect relationships. Clin Pharmacol Ther 1999 ; 65 : 685-694
11. Eissenberg T , Stitzer ML , Bigelow GE et al. Relative potency of levoalpha- acetylmethadol and methadone in humans under acute dosing conditions. J Pharmacol Exp Ther 1999 ; 289 : 936-945
12. Finn P , Wilcock K. Levo-alpha acetyl methadol (LAAM). Its advantages and drawbacks. J Subst Abuse Treat 1997 ; 14 : 559-564
13. Franke GH. Self-Report Symptom Inventory 90 Items Revised. Deutsche Bearbeitung. G ö ttingen, Bern: Beltz Verlag 1995
14. Freedman RR , Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend 1981 ; 8 : 215-222
15. Garbe E , Rö hmel J , Gundert-Remy U. Clinical and statistical issues in therapeutic equivalence trials. Eur J Clin Pharmacol 1993 ; 45 : 1-7
16. Glanz M , Klawansky S , MacAullife W et al. Methadone vs. L-alphaacetylmethadol (LAAM) in the treatment of opiate addiction. A metaanalysis of the randomized, controlled trials. Am J Addict 1997 ; 6 : 339-349
17. Gourevitch MN , Hartel D , Tenore P et al. Three oral formulations of methadone. A clinical and pharmacodynamic comparison. J Subst Abuse Treat 1999 ; 17 : 237-241
18. Grevert P , Masover B , Goldstein A. Failure of methadone and levomethadyl acetate (levo-alpha-acetylmethadol, LAAM) maintenance to aff ect memory. Arch Gen Psychiatry 1977 ; 34 : 849-853
19. Gsellhofer B , Fahrner EN , Platt J. European Addiction Severity Index (EuropASI). M ü nchen: Institut f ü r Therapieforschung 1993
20. Irwin S , Blachly PH , Marks J et al. The behavioral, cognitive and physiologic effects of long-term methadone and methadyl treatment. 1973 [proceedings]. NIDA Res Monogr 1976 ; 8 : 66-67
21. Jaffe JH , Senay EC. Methadone and l-methadyl acetate. Use in management of narcotics addicts. JAMA 1971 ; 216 : 1303-1305
22. Jaffe JH , Senay EC , Schuster CR et al. Methadyl acetate vs. methadone. A double-blind study in heroin users. JAMA 1972 ; 222 : 4 37-442
23. Jaffe JH. Can LAAM, like Lazarus, come back from the dead? Addiction 2007 ; 102 : 1342-1343
24. Johnson RE , Chutuape MA , Strain EC et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000 ; 343 : 1290-1297
25. Jones B , Jarvis P , Lewis JA et al. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996 ; 313 : 36-39
26. Jones HE , Fitzgerald H , Johnson RE. Males and females differ in response to opioid agonist medications. Am J Addict 2005 ; 14 : 223-233
27. Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict 2003 ; 12 (Suppl) : S5-S18
28. Karp-Gelernter E , Savage C , MacCabe OL. Evaluation of clinic attendance schedules for LAAM and methadone: a controlled study. Int J Addict 1982 ; 17 : 805-813
29. Kuo I , Brady J , Butler C et al. Feasibility of referring drug users from a needle exchange program into an addiction treatment program: experience with a mobile treatment van and LAAM maintenance. J Subst Abuse Treat 2003 ; 24 : 67-74
30. Lehmacher W. Ä quivalenznachweise bei Multicenter-Studien. In: Michaelis J, Hommel G, Wellek S, eds. Europäische Perspektiven der Medizinischen Informatik, Biometrie und Epidemiologie. M ü nchen: MMV Medizin Verlag 1993 ; 152-154
31. Ling W , Charuvastra C , Kaim SC et al. Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. Arch Gen Psychiatry 1976 ; 33 : 709-720
32. Ling W , Klett CJ , Gillis RD. A cooperative clinical study of methadyl acetate. I. Three-times-a-week regimen. Arch Gen Psychiatry 1978 ; 35 : 345-353
33. Ling W , Shoptaw S , Wesson D et al. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr 1997 ; 175 : 208-220
34. Ling W , Rawson RA , Compton M. Clinical treatment of opioid addiction and dependence. Methods Mol Med 2003 ; 84 : 285-295
35. Longshore D , Annon J , Anglin MD et al. Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction 2005 ; 100 : 1131-1139
36. Marcovici M , O'Brien CP , MacLellan AT et al. A clinical, controlled study of l-alpha-acetylmethadol in the treatment of narcotic addiction. Am J Psychiatry 1981 ; 138 : 234-236
37. MacCaul ME , Bigelow GE , Stitzer ML et al. Short-term effects of oral methadone in methadone maintenance subjects. Clin Pharmacol Ther 1982 ; 31 : 753-761
38. MacLellan AT , Luborsky L , Woody GE et al. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980 ; 168 : 26-33
39. National Institute of Mental Health 028 CGI. Clinical Global Impressions. In: Goy W, Bonato RR, eds. Manual for the EDCEU assessment battery, 2. rev. ed. Chevy Chase, Maryland 1976
40. Panell J , Charuvastra VC , Ouren J. Methadyl acetate versus methadone: the experience of one hospital. Med J Aust 1977 ; 2 : 150-152
41. Rawson RA , Hasson AL , Huber AM et al. A 3-year progress report on the implementation of LAAM in the United States. Addiction 1998 ; 93 : 533-540
42. Rawson RA , MacCann MJ , Hasson AJ et al. Addiction pharmacotherapy 2000: new options, new challenges. J Psychoactive Drugs 2000 ; 32 : 371-378
43. Reilly JG , Ayis SA , Ferrier IN et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000 ; 355 : 1048-1052
44. Ritter AJ , Lintzeris N , Clark N et al. A randomized trial comparing levoalpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction 2003 ; 98 : 1605-1613
45. R ö hmel J. Therapeutic equivalence investigations: statistical considerations. Stat Med 1998 ; 17 : 1703-1714
46. Savage C , Karp EG , Curran SF et al. Methadone/LAAM maintenance: a comparison study. Compr Psychiatry 1976 ; 17 : 415-424
47. Senay EC , Dorus W , Renault PF. Methadyl acetate and methadone. An open comparison. JAMA 1977 ; 237 : 138-142
48. Stimmel B. Maintenance therapy for opioid addiction with methadone, LAAM and buprenorphine: The emperor's new clothes phenomenon. J Addict Dis 2001 ; 20 : 7-14
49. Tennant FS , Rawson RA , Pumphrey E et al. Clinical experiences with 959 opioid dependent patients treated with l-alpha acetymethadol (LAAM). J Subst Abuse Treat 1986 ; 3 : 195-202
50. Ulrich S , Hiemke C , Laux G et al. TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: a comparison with the medicoscientifi c evidence. Pharmacopsychiatry 2007 ; 40 : 121-127
51. Walsh SL , Johnson RE , Cone EJ et al. Intravenous and oral l-alphaacetylmethadol: pharmacodynamics and pharmacokinetics in humans. J Pharmacol Exp Ther 1998 ; 285 : 71-82
52. Zaks A , Fink M , Freedman AM. Levomethadyl in maintenance treatment of opiate dependence. JAMA 1972 ; 220 : 811-813